Recipharm offers services to enable switch to next generation pMDI propellants
Global contract development and manufacturing organisation (CDMO) Recipharm, today announces that it is expanding its pMDI product development expertise to accommodate the increasing demand from pharmaceutical companies as they begin the transition to the next generation of propellants over the coming years. These new propellant gases have 90% to 99.9% lower global warming potential (GWP) than HFA134a. Jean-François Hilaire, Head of the Advanced Delivery Systems business unit at Recipharm, said: “We are committed to decarbonisation and helping our customers meet their sustainability